Therapeutic Response of Human Occipital, Breast and Oral Cavity Tumors to Paclitaxel in NOD SCID Mice


Author(s): Arvind D Ingle* and Basaling B Hosetti

Preclinical chemotherapeutic drug screening is performed using cultured tumor cells or human tumor

xenografts. However, direct correlation is not established between the response of mouse and human patients.

Factors like tumor size at which treatment is initiated, schedule and doses of treatment etc. are important for the

success of such screenings. The present study was undertaken to assess in vivo response of squamous cell

carcinoma of occipital region, carcinoma of breast and squamous cell carcinoma of oral cavity collected from the

operation theater of ACTREC to Paclitaxel. Pieces of tumor from occipital and oral cavity were grown

subcutaneously in NOD SCID mice whereas breast tumor was grown orthotopically near the mammary fat pad.

Paclitaxel treatment was given at the dose of 25 mg/kg body weight on 1, 5 and 9th day after the tumor attained

the size of 50-300 mm3. Treatment group animals showed significant tumors growth delay by 12 weeks. Occipital

tumor group showed significant growth delay as well as anticancer activity when maintained for extended period of

22 weeks whereas breast and oral cavity tumor did not show anticancer activity when maintained for 19-20 weeks.

The results of the present study warrant systematic study using varying doses and/or duration of treatment.

Get the App